Showing results (351-360 of 1,071) with videos related to

Sort By:
Pageof 108
Journal of Asian Natural Products Research|July 15, 2011
Three new glycosides from Hylocereus undatusXin Wu, Ying Wang, Xiao-Jun Huang, et al.
American Journal of Hematology|February 4, 2018
N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantationYuan Kong, Min-Min Shi, Yuan-Yuan Zhang, et al.
Chemistry & Biodiversity|April 9, 2019
Cablinosides A and B, Two Glycosidic Phenylacetic Acid Derivatives from the Leaves of Pogostemon cablinXiao-Jun Huang, Ping Li, Zhi-Qi Yin, et al.
Journal of Materials Chemistry. B|February 9, 2022
Janus membranes with asymmetric cellular adhesion behaviors for regenerating eardrum perforationZhili Zhang, Jin-Bo Li, Xu Li, et al.
Food Chemistry|August 16, 2021
Revealing the architecture and solution properties of polysaccharide fractions from Macrolepiota albuminosa (Berk.) PeglerYu-Xiao Wang, Yue Xin, Jun-Yi Yin, et al.
American Journal of Cancer Research|February 14, 2025
A novel reduced toxicity conditioning regimen for older myelodysplastic neoplasms patients undergoing haploidentical stem cell transplantation: a prospective cohort studyWen-Jing Yu, Yu-Qian Sun, Xiao-Hui Zhang, et al.
Cancer Communications (London, England)|February 10, 2021
Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donorsYu-Qian Sun, Lan-Ping Xu, Kai-Yan Liu, et al.
Neuroscience Letters|December 3, 2015
Novel ATM mutations with ataxia-telangiectasiaXiao-Li Liu, Tian Wang, Xiao-Jun Huang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 7, 2008
[Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, et al.
Leukemia & Lymphoma|October 14, 2016
Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinibYa-Zhen Qin, Qian Jiang, Yue-Yun Lai, et al.
Pageof 108